Multidisciplinary

Top Medical News
an hour ago
Infants born preterm and with very low birthweight (VLBW) appear to sustain altered cardiovascular structure and function in adulthood, a new study has found.
2 hours ago
Pregabalin, used either alone or in combination with milnacipran, is effective in the treatment of patients with fibromyalgia, and combined therapy does not confer added benefits compared with monotherapy, according to a study.
4 hours ago
In patients with decompensated cirrhosis, β-blockers trigger a stronger systemic haemodynamic response and exert a weaker portal pressure-lowering effect, a recent study has found.
Rachel Soon, 10 hours ago

A new patient-centred website for Malaysians with endometriosis has been launched by the Endometriosis Association of Malaysia (MyEndosis).

Roshini Claire Anthony, 15 hours ago

Low-dose colchicine reduced the risk of multiple cardiovascular (CV) outcomes in patients with chronic coronary disease, according to the LoDoCo2* trial presented at ESC 2020.

16 hours ago
Regardless of endometriosis, dyspareunia is common among adolescents and young adult women, and it negatively impacts their physical and mental quality of life (QOL), a recent study has found.
Pearl Toh, 19 hours ago
Inhaled treprostinil significantly improves exercise capacity in terms of 6-minute walking distance (6MWD) over 16 weeks compared with placebo in patients with pulmonary hypertension associated with interstitial lung disease (ILD), according to the INCREASE trial presented at ATS 2020.
Special Reports
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Audrey Abella, 21 Sep 2020
Single-inhaler triple-therapy (SITT) comprising FF/UMEC/VI* is preferred over dual therapies (DT) or multiple-inhaler (MI) TT for managing COPD**, according to data presented at ERS 2020.
Pearl Toh, 16 Sep 2020
Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.
16 Sep 2020
XOFLUZA – Baloxavir marboxil 20 mg and 40 mg FC tab
16 Sep 2020
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
16 Sep 2020
GALVUS MET – Vidagliptin, metformin HCl 50 mg/500 mg, 50 mg/850 mg and 50 mg/1,000 mg FC tab
16 Sep 2020
COSYREL – Bisoprolol fumarate, perindopril arginine 5 mg/5 mg, 5 mg/10 mg and 10 mg/10 mg FC tab
Conference Reports
Roshini Claire Anthony, 25 Sep 2020

Low-dose colchicine reduced the risk of multiple cardiovascular (CV) outcomes in patients with chronic coronary disease, according to the LoDoCo2* trial presented at ESC 2020.

Pearl Toh, 25 Sep 2020
Inhaled treprostinil significantly improves exercise capacity in terms of 6-minute walking distance (6MWD) over 16 weeks compared with placebo in patients with pulmonary hypertension associated with interstitial lung disease (ILD), according to the INCREASE trial presented at ATS 2020.
Roshini Claire Anthony, 24 Sep 2020

For patients with unresectable malignant pleural mesothelioma (MPM), nivolumab plus ipilimumab in the first-line setting demonstrated greater overall survival (OS) than standard-of-care (SoC) platinum chemotherapy, interim analysis of the phase III CheckMate743 trial revealed.

Roshini Claire Anthony, 23 Sep 2020

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.

Pearl Toh, 23 Sep 2020
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, 22 Sep 2020

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Audrey Abella, 22 Sep 2020
The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download